<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03823924</url>
  </required_header>
  <id_info>
    <org_study_id>2017_39</org_study_id>
    <secondary_id>2018-A01552-53</secondary_id>
    <nct_id>NCT03823924</nct_id>
  </id_info>
  <brief_title>Changes in Body Composition Under Ustekinumab in PsA</brief_title>
  <acronym>STELARA-CC</acronym>
  <official_title>Body Composition and Bone Mineral Density in Patients With Psoriatic Arthritis and Changes After 6 Months of Treatment With Ustekinumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is not much body composition and bone mineral density data available for patients with&#xD;
      psoriatic arthritis (rheumatoid arthritis) compared to control subjects.&#xD;
&#xD;
      The evaluation of the total fat mass and in particular of its abdominal distribution&#xD;
      (visceral adiposity) is important because an excessive adiposity generates adverse effects on&#xD;
      the health (hypertension, dyslipidemia, cardiovascular risk and resistance to the insulin).&#xD;
&#xD;
      In addition, data on changes in body composition and bone mineral density were not available&#xD;
      under a new psA treatment, namely ustekinumab (anti-IL12 / 23 antibody).&#xD;
&#xD;
      It is proposed to conduct a pilot study to evaluate body composition, distribution (visceral&#xD;
      adiposity) and bone mineral density in patients with psoriatic arthritis (versus control&#xD;
      subjects) and their changes after 6 months of treatment with ustekinumab&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2019</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Visceral adiposity (VAT)</measure>
    <time_frame>At baseline</time_frame>
    <description>Comparison at baseline of visceral adiposity (VAT) in cm² between PsA (n = 30) and healthy volunteers (n = 30) matched on age (± 5 years, ≥ 18 years), sex, menopausal status for women and body mass index (BMI, ± 3 kg / m²).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total lean mass</measure>
    <time_frame>At baseline</time_frame>
    <description>Comparison at baseline of total lean mass (TLM, kg), between PsA (n = 30) and healthy volunteers (n = 30) matched on age (± 5 years, ≥ 18 years), sex, menopausal status for women and body mass index (BMI, ± 3 kg / m²).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total fat mass</measure>
    <time_frame>At baseline</time_frame>
    <description>Comparison at baseline of total fat mass (TBF, %) between PsA (n = 30) and healthy volunteers (n = 30) matched on age (± 5 years, ≥ 18 years), sex, menopausal status for women and body mass index (BMI, ± 3 kg / m²).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density</measure>
    <time_frame>At baseline</time_frame>
    <description>Comparison at baseline of bone mineral density (BMD, g/cm²) between PsA (n = 30) and healthy volunteers (n = 30) matched on age (± 5 years, ≥ 18 years), sex, menopausal status for women and body mass index (BMI, ± 3 kg / m²).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total fat mass (TBF, %) under ustekinumab in PsA</measure>
    <time_frame>at baseline and at 6 months (± 2 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total lean mass (TLM, kg) under ustekinumab in PsA</measure>
    <time_frame>at baseline and at 6 months (± 2 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visceral adiposity (cm²) under ustekinumab in PsA</measure>
    <time_frame>at baseline and at 6 months (± 2 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone mineral density (BMD, g/cm²) under ustekinumab in PsA</measure>
    <time_frame>at baseline and at 6 months (± 2 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in makers of bone remodeling under ustekinumab in PsA</measure>
    <time_frame>at baseline and at 6 months (± 2 months)</time_frame>
    <description>C-telopeptide (Ctx), Procollagen type 1 amino-terminal propeptide (P1NP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in leptin under ustekinumab in PsA</measure>
    <time_frame>at baseline and at 6 months (± 2 months)</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Psoriatic arthritis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone mineral density (BMD)</intervention_name>
    <description>The bone mineral density (BMD) performed by DXA, which will allow the analysis of bone density (mg / cm²) at the lumbar spine (BMD L1 to L4) and the total hip (non-dominant).&#xD;
This examination will also allow an analysis of the body composition at the same time (lean mass, fat mass and bone mass for the whole body).</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Psoriatic arthritis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with psoriatic arthritis and controls&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Psoriatic arthritis:&#xD;
&#xD;
               1. Men and women ≥ 18 years&#xD;
&#xD;
               2. Patients with PsA according to CASPAR criteria,&#xD;
&#xD;
               3. Patients who do not have yet started ustekinumab,&#xD;
&#xD;
               4. Patients who signed the informed consent.&#xD;
&#xD;
          -  Healthy volunteers:&#xD;
&#xD;
               1. Men and women ≥ 18 years&#xD;
&#xD;
               2. Patients who signed the informed consent.&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
          -  Items 1 to 10 are applicable to healthy volunteers and PsA&#xD;
&#xD;
               1. History of fragility fracture AND / OR T-score ≤-3 if ≥50 years AND / OR Z-score&#xD;
                  ≤-3 if &lt;50 years during the screening phase,&#xD;
&#xD;
               2. Corticosteroids ≥10 mg / day,&#xD;
&#xD;
               3. Diseases or treatments affecting bone metabolism (breast cancer with&#xD;
                  anti-aromatase, malabsorption, primary hyperparathyroidism, uncontrolled&#xD;
                  hyperthyroidism ...),&#xD;
&#xD;
               4. History of radiotherapy on the lumbar spine or hip,&#xD;
&#xD;
               5. Patients undergoing hormone replacement therapy (HRT) or patients already on&#xD;
                  anti-osteoporotic therapy (bisphosphonates, strontium ranelate, teriparatide or&#xD;
                  denosumab),&#xD;
&#xD;
               6. Chronic kidney disease with creatinine clearance (CKD-EPI) ≤ 30 ml / min,&#xD;
&#xD;
               7. Weight&gt; 160 kg,&#xD;
&#xD;
               8. Patients under restrictive diet or considering a diet of this type during the&#xD;
                  study period,&#xD;
&#xD;
               9. Patients who have an intense exercise program or plan to benefit from it during&#xD;
                  the study period,&#xD;
&#xD;
              10. Pregnant or lactating women or having a pregnancy project,&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien Paccou, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien Paccou, MD,PhD</last_name>
    <phone>03 20 44 69 26</phone>
    <phone_ext>+33</phone_ext>
    <email>julien.paccou@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Roger Salengro, CHU</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Julien Paccou, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 14, 2019</study_first_submitted>
  <study_first_submitted_qc>January 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2019</study_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriatic arthritis</keyword>
  <keyword>ustekinumab</keyword>
  <keyword>body composition</keyword>
  <keyword>bone mineral density</keyword>
  <keyword>adiposity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

